Journal
FUTURE MICROBIOLOGY
Volume 15, Issue 6, Pages 389-400Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fmb-2019-0288
Keywords
adenovirus; allogeneic stem cell transplant; BCV; brincidofovir; cidofovir diphosphonate; CMX001; dsDNA virus
Categories
Ask authors/readers for more resources
Brincidofovir (BCV) is a lipid conjugate of cidofovir with good oral bioavailability, enabling optimal intracellular levels of the active drug. Lower rates of nephrotoxicity and myelotoxicity make it a favorable alternative. Despite a greater safety profile among pediatric hematopoietic cell transplant recipients, the oral formulation has been associated with increased gastrointestinal toxicity in adult hematopoietic cell transplant recipients. Oral BCV continues to be developed as a countermeasure against smallpox, while a potentially safer intravenous preparation has been out licensed to another company. BCV has demonstrated great in vitro potency against double-stranded DNA viruses, especially adenovirus. Because of its importance for immunocompromised patients, this review aims to evaluate BCV's clinical and safety profile to support its continued development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available